The recent advancements by Acurx Pharmaceuticals, Inc. in the development of ibezapolstat, including the scheduling of an End of Phase 2 (EOP2) meeting with the FDA for late April 2024 and the acquisition of SME designation from the European Medicines Agency (EMA), are bullish indicators for the company and its stakeholders. These milestones are significant as...
ACXP - Already made money on it... Now Waiting for it to touch the support so I can Jump in.
Play the swing up from the bottom. On big news, it can breakout.
close up resistance price close up 50 EMA 2- RSI up 60% 3- MACD UP 80 Then target 7.77 stop lose 4.91
Acurx filed a provisional patent application with the U.S. Patent and Trademark Office for use of ibezapolstat to treat C. difficile Infection (CDI) while reducing recurrence of infection and improving the health of the gut microbiome. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The Company...
Considering the IPO within the last months, $ACXP has proven to investor its ability to hold value although its SP is not trading alike. Do not be fooled by the numbers, the company has had prior success with EUA and applications via FDA. Though private during inception, the company seeks to fund its ongoing pipeline with diversity. Their current target product...
NASDAQ:ACXP is building a steady support line, possible trend upwards. PT 7.5 short term.